MedPath

Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Placebo Oral Tablet
Registration Number
NCT03402984
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

Introduction. Functional dyspepsia (FD) is a common chronic gastrointestinal disorder with a high socio-economic impact. Acotiamide, a new prokinetic agent, was shown to be efficacious in the treatment of FD, especially in the postprandial distress syndrome subgroup. To date, the exact mechanism of action of acotiamide is incompletely elucidated.

The aim of this study was to examine the effect of acotiamide on gastric motility, gastric emptying rate and gastrointestinal symptom perception in healthy participants in a randomized, placebo-controlled, cross-over study design. Participants were treated with acotiamide (100 mg t.i.d.) and placebo for 3 weeks, separated by a one-week wash-out period. At the end of each treatment period, gastric emptying and motility were assessed on two consecutive study days. During gastric motility assessment, epigastric symptom scores were collected at multiple time points.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • age: 18-60 years old.
  • Participant must provide witnessed written informed consent prior to any study procedures being performed.

Exclusion criteria:

  • Age > 60 years old.
  • severely decreased kidney function.
  • severely decreased liver function.
  • severe heart disease, for example a history of irregular heartbeats, angina or heart attack.
  • severe lung disease.
  • severe psychiatric illness or neurological illness.
  • any gastrointestinal disease.
  • any dyspeptic symptoms.
  • pregnant or breastfeeding.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo Oral TabletPlacebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
AcotiamideAcotiamideAcotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
Primary Outcome Measures
NameTimeMethod
Gastric accommodationGastric pressure was measured until 1 hour after the start of the liquid meal. Liquid meal started 10 minutes after medication/placebo intake

Relaxation of the stomach upon food intake

Secondary Outcome Measures
NameTimeMethod
Gastric emptyingBreath samples were collected before intake of medication/placebo and every 15 minutes until 4h after intake of 13C-octanoid acid

Gastric emptying was assess by a 13C-octanoid acid breath test

Change in subjective gastrointestinal symptom scores measured by visual analogue scale of 100 mmassessment by questionnaire (100 mm Visual Analogue Scale) every 5 minutes, up to 1 hour after administration of the liquid meal

Trial Locations

Locations (1)

Jan Tack

🇧🇪

Leuven, Belgium

© Copyright 2025. All Rights Reserved by MedPath